From November 10 to 14, 2023, the American Association for the Study of Liver Disease (AASLD) The Liver Meeting was held in Boston, Massachusetts, USA. The Liver Meeting brought together the latest research progress in liver diseases worldwide. Three important research results from the teams led by Professor He Yingli and Professor Zhao Yingren from Department of Infectious Diseases of the First Affiliated Hospital of ( FAH) Xi'an Jiaotong University (XJTU) were released at The Liver Meeting 2023.
Two studies by doctoral students tutored by Professor He Yingli and 1 study by Professor Zhao Yingren were presented at the meeting. At AASLD The Liver Meeting, 3 posters were presented. Doctoral student Zhang Qiao contributed a poster entitled “A novel prognostic model based on portal vein diameter for patients with acute-on-chronic liver failure”. Postgraduate student Zang Qijuan delivered a poster entitled “Compensable safety and efficacy of tenofovir alafenamide with tenofovir disoproxil fumarate in pregnant women: systematic review with meta-analysis”. Doctoral student Wang Ruojing contributed a poster entitled “Effectiveness and safety of mother-to-child medication for HBV and HIV infection”, respectively.
These significant achievements have been made by the teams led by Professor Zhao Yingren and Professor He Yingli in the study of mother-to-child medication for hepatitis B, liver cirrhosis and prognosis of liver failure since the construction of National Regional Medical Center for Infectious Diseases, which fully reflect that the diagnosis, treatment and research levels of infectious diseases in the field of liver diseases have been highly recognized by international peers!
Professor He Yingli's team has been devoted to the study of liver failure, and established a database and specimen database for liver failure, which is the third largest database for liver failure in China. Professor He Yingli's team has carried out liver failure-related research for more than 20 years, and received financial supports from 8 National Natural Science Foundation of China projects in the field of liver failure, and the first prize of Science and Technology Award of Shaanxi Province due to in-depth research on the pathogenesis, antiviral treatment, dynamic changes of liver volume and clinical treatment of liver failure.
In terms of clinical diagnosis and treatment, Director He Yingli’s team has been able to deliver artificial liver treatment. The department was approved as "National Demonstration Center for Artificial Liver and Blood Purification Technology" in 2019. The number of therapeutic devices has been increased from 1 to 10. The number of nursing staff has been increased from 1 to 8. The therapeutic technologies have been evolved from simple plasma exchange to tens of treatment modes. The number of patients each month has been expanded from several cases to 130. A professional and refined treatment team has been formed.
